Figure 2.

Enhanced Multilineage Repopulating Activity of IK6-Transduced Human CD34⁺ CB Cells

(A) Experimental design.

(B) Ratio of ABL1/B2M normalized IKZF1 transcript levels in transduced CD34⁺ human cell subsets generated in NSG mice (mean ± SEM, four mice).

(C) Representative flow cytometric profiles of total IKAROS protein in human cells generated in five NSG mice (dotted line shows unstained control).

(D) Paired comparisons of total IK6- and control-derived human CD45⁺ cells in individual mice transplanted 8–10 weeks previously (24 mice from five cohorts).

(E and F) Ten-week posttransplant levels of human CD19⁺ and surface immunoglobulin M⁺ (B), CD3⁺ (T), and CD33⁺ (GM) cells in the same mice shown in (D).

(G) Platelet levels in the blood of NSG mice transplanted 4–10 weeks previously (mean ± SEM; seven mice from two cohorts).

(H) Colonies derived from equal numbers of IK6- and control-transduced myeloerythroid progenitors sorted from the BM of NSG mice transplanted 10 weeks previously (mean ± SEM; three mice).

(I) Levels of different human CD34⁺ subsets in the BM of primary NSG mice transplanted 10 weeks previously (mean ± SEM, 14 mice).

Progenitor-enriched fractions: multipotent, CD34⁺CD38⁻; lymphoid, CD34⁺CD38⁺CD10⁺; myeloerythroid, CD34⁺CD38⁺CD45RA⁻FLT3⁺; granulopoietic, CD34⁺CD38⁺CD45RA⁺FLT3⁺. BFU-E, burst-forming unit-erythroid; CFC-GM, colony-forming cell-GM. ^∗p < 0.05; ^∗∗p < 0.01; ^∗∗∗p < 0.001. See also Figure S2.